Histopathological Characterization of Mitral Valvular Lesions from Patients with Rheumatic Heart Disease

Nayana F. A. Gomes,¹ Marcelo A. Pascoal-Xavier,¹ Livia S. A. Passos,¹ Thiago Mendonça Nunes Paula,¹ João Marcelo de Souza Aguiar,¹ Felipe Vieira Guarçoni,¹ Maria Cecília Landim Nassif,¹ Claudio Leo Gelape,¹ Renato Braulio,¹ Paulo Henrique N. Costa,¹ Luiz Guilherme Passaglia,¹ Raquel Braga Martins,¹ Walderez O. Dutra,¹ Maria Carmo P. Nunes¹

Universidade Federal de Minas Gerais,¹ Belo Horizonte, MG - Brazil

Abstract

Background: The underlying mechanisms by which rheumatic heart disease (RHD) lead to severe valve dysfunction are not completely understood.

Objective: The present study evaluated the histopathological changes in mitral valves (MV) seeking an association between the pattern of predominant valvular dysfunction and histopathological findings.

Methods: In 40 patients who underwent MV replacement due to RHD, and in 20 controls that underwent heart transplant, histological aspects of the excised MV were analyzed. Clinical and echocardiographic data were also collected. Histological analyses were performed using hematoxylin-eosin staining. Inflammation, fibrosis, neoangiogenesis, calcification and adipose metaplasia were determined. A p value<0.05 was considered to be statistically significant.

Results: The mean age of RHD patients was 53±13 years, 36 (90%) were female, whereas the mean age of controls was 50±12 years, similar to the cases, with the majority of males (70%). The rheumatic valve endocardium presented greater thickness than the controls (1.3±0.5 mm versus 0.90±0.4 mm, p=0.003, respectively), and a more intense inflammatory infiltrate in the endocardium (78% versus 36%; p=0.004), with predominance of mononuclear cells. Moderate to marked fibrosis occurred more frequently in rheumatic valves than in control valves (100% vs. 29%; p<0.001). Calcification occurred in 35% of rheumatic valves, especially among stenotic valves, which was associated with the mitral valve area (p=0.003).

Conclusions: Despite intense degree of fibrosis, the inflammatory process remains active in the rheumatic mitral valve, even at late disease with valve dysfunction. Calcification predominated in stenotic valves and in patients with right ventricular dysfunction. (Arq Bras Cardiol. 2021; 116(3):404-412)

Keywords: Rheumatic Disease; Calcification; Fibrosis; Inflammation; Rheumatic Fever; Myocarditis; Histology; Mitral Valve Stenosis; Echocardiography/methods.

Introduction

Rheumatic heart disease (RHD) remains a major public health concern, especially in low- and middle-income countries, where it is the leading cause of cardiovascular death in children and young adults.¹ ² It is estimated that 33 million individuals currently live with RHD, accounting for over a million premature deaths annually.¹ RHD has the highest cardiovascular disease-related loss of disability-adjusted-life-years (DALY) in children worldwide.³ Much of the morbidity and mortality of RHD can be prevented, but if left untreated, subsequent heart failure and death are inevitable.⁴ ⁵ Most deaths occur in young adults, who would otherwise be at the most productive years of their lives, indicating the devastating impact of this condition.⁴ ⁵ ⁶

RHD is a harmful post-infectious sequel of acute rheumatic fever (ARF) resulting from an abnormal immune response to a streptococcal pharyngitis that triggers valvular damage.⁶ Unlike myocardium and pericardium, the valvular tissue often sustains permanent damage after active initial carditis.⁷ In the late stage of RHD, ongoing chronic inflammation continues leading to pathological valve remodeling that perpetuates valve damage over time.⁸ ⁹ ¹⁰ ¹¹ RHD most commonly and severely affects the mitral valve (MV) which, over time becomes dysfunctional, contributing to an increased risk of death and other major adverse outcomes.

Despite the observed progress in research on RHD pathogenesis, a number of key scientific questions remain.¹² ¹³ Specifically, the underlying mechanisms involved in the development of severe valve dysfunction are not completely understood.¹⁴ An active inflammatory process and endothelial...
activation are fundamental to perpetuate the progressive fibrotic leaflet remodeling and further valve dysfunction. Therefore, an improved understanding of this pathological process that leads to the development of severe valve dysfunction will provide insights into disease pathogenesis, and can ultimately lead to more effective therapeutic strategies to prevent irreversible valvular damage. In the present study, we hypothesized that the inflammatory process persists even in more advanced stages of the disease process, which contributes to progressive valve injury in RHD. The aim of this study is to evaluate the histopathological changes in mitral valves at an end stage of valve dysfunction, seeking an association between the pattern of predominant valvular dysfunction and histopathological findings.

Methods

Study population

A total of 60 mitral valves were collected from January 2015 to 2018, 40 were from RHD patients, and 20 were in the control group, which included all patients who underwent heart transplant due to severe heart failure, without primary valve lesion.

Patients referred to the University Hospital of Universidade Federal de Minas Gerais (HC-UFMG) diagnosed with rheumatic mitral valve disease, presenting stenosis or regurgitation, and with indication to mitral valve replacement surgery were eligible for the study.

The patients were informed about the study and invited to participate, voluntarily, during their follow-up before the surgical procedure. Treatment was offered to all patients, regardless of their willingness to participate in the study, and all those who agreed to participate signed an informed consent form. This study was approved by the Ethics Committee of Universidade Federal de Minas Gerais.

Clinical consultation, anamnesis and physical examination were performed to collect the clinical data prior to surgery, and the echocardiogram was performed at HC-UFMG Echocardiography Sector, for the collection of echocardiographic and imaging data.

Patient management and indication for mitral valve replacement was according to the recommended guidelines for valvular heart disease.

Surgeries were performed in the HC-UFMG Surgery Center and the valves were sent to the HC-UFMG Pathology Department for conventional histopathological examination, according to the routine established by the Cardiovascular and Cardiovascular Surgery Service of HC-UFMG, as well as the Laboratory of Molecular Pathology (LMP) of the Department of Pathological Anatomy and Legal Medicine of FM-UFMG, to carry out this study.

Echocardiographic evaluation

Two-dimensional (2D) echocardiography imaging and Doppler was performed using a commercially available system (Philips ie33, Andover, MA or GE Vivid-q Horten, Norway) in all patients. Standard echocardiograms were obtained according to the American Society of Echocardiography guidelines. The conventional indexes for assessment of mitral stenosis severity, including mitral valve area, transmitral valve pressure gradients and pulmonary artery systolic pressure were measured, as recommended.

Histological analysis

The valves received in the LMP were examined and referred for histological processing according to routine laboratory protocols, including fixation, paraffin embedding, hematoxylin-eosin staining and microscopic analysis. Semi-quantitative analysis of the samples was carried out using a grade scale.

Parameters of inflammation intensity, identification of the predominant cell type and fibrosis intensity were evaluated, in addition to the presence of neoangiogenesis, calcification and adipose metaplasia.

Endocardial thickness was determined in millimeters. Intensity of inflammation and fibrosis was semi-quantitatively graded as absent, mild, moderate and severe by 2 independent observers with subsequent analysis by an experienced pathologist who made the final classification. The presence of neoangiogenesis, calcification and adipose metaplasia was defined as absent or present.

Statistical analysis

Categorical variables, expressed as numbers and percentages, were compared using chi-squared testing. Normality of continuous variables was tested using the Shapiro-Wilk test, and data with normal distribution were expressed as mean±standard deviation (SD) and differences between inflammation intensity categories, valve area and leaflet thickness were assessed using Student’s unpaired t-test. Mean valve area and leaflet thickness were compared in 3 categories of inflammation, using one-way ANOVA test and post hoc analysis with Tuckey’s test. Differences that returned P values of <0.05 were considered statistically significant. Statistical analysis was performed using the Statistical Package for Social Sciences for Windows, version 22.0 (SPSS Inc., Chicago, Illinois).

Results

Patient characteristics

The mean age of the patients was 53±13 years and 36 (90%) were females. The characteristics of the study population comparing patients with controls are summarized in Table 1. The majority of the patients were in NYHA functional class III and IV (60%). Figure 1 shows representative pictures of the anatomical characteristics of mitral valves from controls and patients.

Preoperative medications most frequently used were diuretics (60%) and beta-blockers (55%). Patients with atrial fibrillation and/or previous stroke were taking anticoagulants. Thirteen patients (33%) were using penicillin benzathine for secondary prevention of rheumatic fever. The mean age of these patients was 47.9±11.3. None of the patients...
Table 1 – Demographic, clinical and echocardiographic data of the patients who underwent mitral valve replacement due to rheumatic heart disease comparing with controls who underwent heart transplant

| Variables* | Rheumatic mitral valves (n=40) | Controls (n=20) | p value |
|------------|-------------------------------|----------------|---------|
| Age (years) | 53±13.2                      | 50±11.6        | 0.334   |
| Female gender | 36 (90)                      | 6 (30)         | <0.001  |
| Functional class III/IV | 24 (60)                  | 16 (80)        | 0.003   |
| Right-sided heart failure | 12 (30)                   | 12 (60)        | 0.030   |
| Previous mitral valvuloplasty | 22 (55)                 | ...            | ...     |
| Previous history of acute rheumatic fever | 27 (68)                 | ...            | ...     |
| Use of antibiotic prophylaxis | 13 (33)                   | ...            | ...     |
| Atrial fibrillation | 24 (60)                    | 5 (25)         | 0.003   |
| Previous stroke | 12 (30)                    | 4 (20)         | 0.102   |
| Previous hospitalization for heart failure | 17 (43)                   | 20 (100)       | <0.001  |

Echocardiographic parameters

| Variables* | Rheumatic mitral valves | Controls | p value |
|------------|-------------------------|----------|---------|
| Left ventricular end-diastolic diameter (mm) | 51.7±10.9 | 66.3±7.6 | <0.001 |
| Left ventricular end-systolic diameter (mm) | 35.8±8.6  | 57.148.2 | <0.001 |
| Left ventricular ejection fraction (%) | 60.6±10.5 | 26.5±7.5 | <0.001 |
| Mitral valve area (cm²) | 1.18±0.37 | ... | ... |
| Left atrial diameter (mm) | 55.1±10.5 | 48.9±6.4 | 0.006 |
| Pulmonary artery systolic pressure (mmHg) | 46.5±18.3 | 39.7±16.8 | 0.292 |
| Right ventricular dysfunction | 16 (40)   | 9 (45)   | 0.785   |

*Data are expressed as mean±SD or number (percentage) of patients.

Figure 1 – Gross morphological aspects of the mitral valves from controls and patients with rheumatic heart disease. Note that the in rheumatic valves, and the anterior and posterior mitral leaflets are fused at the commissures. The chordae are shortened and fused.
included in the study had clinical evidence of active acute rheumatic fever.

Regarding the pattern of valve involvement, 18 patients (45%) had pure mitral stenosis, 14 patients (35%) had mixed mitral valve disease, and 8 patients (20%) displayed predominantly mitral regurgitation. Aortic lesion was detected in the echocardiogram of 15 patients (38%). Valvuloplasty had previously been performed in 22 patients (55%), including either percutaneous or surgical intervention. Surgical indication for complications of percutaneous valvuloplasty occurred in 6 patients (15%), 4 of whom due to severe mitral regurgitation related to leaflet or subvalvar apparatus damage. Among those who developed severe mitral regurgitation, 2 patients presented tear of the anterior leaflet and underwent emergency surgery for valve replacement. Two patients had laceration of P3 and A3 scallops in contiguity with postero medial commissure, and posterior leaflet at central scallop location (P3), respectively, and underwent elective surgery for valve replacement. The other 2 patients presented worsening of mitral regurgitation after the procedure with suboptimal valve opening.

The control group consisted of 20 patients who underwent cardiac transplant, with mean age of 50±12 years, similar to the cases of RHD, with the majority of males (70%). The causes of heart failure were Chagas dilated cardiomyopathy (9 patients), cardiomyopathy after myocarditis (3), ischemic cardiomyopathy (3), idiopathic dilated cardiomyopathy (4) and retransplantation due to autoimmune rejection to the graft (1). Secondary moderate to severe mitral regurgitation was found in 7 patients (35%). The other echocardiographic data are shown in Table 1.

**Histopathology analysis of rheumatic mitral valves**

The endocardium with rheumatic mitral valves was thicker (1.3±0.5 vs. 0.9±0.4 mm) with greater intensity of fibrosis and inflammatory infiltrate compared with controls (Figures 2A and B). The histological findings of rheumatic mitral valves comparing to controls are shown in Table 2. Overall, rheumatic valves presented inflammation of mild intensity, focal distribution and predominance of mononuclear cells, and fibrosis of moderate to severe intensity (Figures 2C and D). Among patients using benzathine penicillin, 9 (69%) had mild inflammation. Neoangiogenesis was more frequent in rheumatic mitral valves than in controls (Figures 2E and F).

None of the valves of the control group presented calcification whereas 35% of rheumatic valves had calcification (Figure 2G). Only a small portion of the valves in both groups had adipose metaplasia (Figure 2H).

According to the type of rheumatic mitral valve lesion, calcification was more frequent in pure mitral stenosis compared with mitral regurgitation or mixed lesions. Histological data according to the predominant mitral valve lesion that required valve replacement are shown in Table 3. We further stratified the patients into 3 groups according to inflammation intensity in low, moderate and high to correlate with the mitral valve area. We observed that the patients with a higher degree of inflammation and without calcification had a larger mitral valve area (Figures 3A and B, respectively). There were no differences regarding leaflet thickness and inflammation intensity (Figure 3C) nor neoangiogenesis and mitral valve area (Figure 3D).

**Echocardiographic parameters associated with histological findings**

Echocardiographic parameters and histological findings were further compared. We observed an association between left ventricular systolic function, assessed by ejection fraction, and intensity of inflammation. Patients with left ventricular dysfunction, defined by ejection fraction less than 50%, showed a predominance of moderate to marked inflammation compared to patients with preserved ventricular systolic function (50% and 12% respectively, p=0.023). While valvular calcification was not associated with left ventricular dysfunction, patients with right ventricular dysfunction had a higher calcification compared with patients with normal right ventricular function (56% and 21% respectively, p=0.021), which may be related to the type of lesion associated with calcification.

**Discussion**

Leaflet tissue inflammation and fibrosis play a central role to induce progressive valve damage in RHD. The present study evaluated rheumatic mitral valves in the end-stage of RHD when life-threatening valve dysfunction required surgery for valve replacement. The histological findings from rheumatic valves were compared with excised mitral valves from patients who underwent cardiac transplant, without primary valve disease.

Analysis of histological data showed marked fibrosis among all rheumatic valves, showing that continued fibrosis perpetuates throughout RHD progression. The fibrotic state of the mitral valve precedes myocardial dysfunction and manifest heart disease, making it important to develop diagnostic and therapeutic strategies to reduce structural remodeling of heart valves.

Notably, even though patients are later in their disease, the valves continue to show active inflammatory processes, predominantly composed of mononuclear cells. The intensity of inflammation was associated with mitral valve area, but not with leaflet thickness. Low inflammatory intensity was found in a smaller valve area, probably due to fibrosis intensity that has an inverse association with the degree of inflammation.

Patients with left ventricular dysfunction presented a higher degree of valve inflammation, which may indicate adjacent myocarditis. However, 4 of the patients with left ventricular dysfunction had mitral insufficiency as the predominant lesion that may be the cause of the left ventricular dysfunction, which is an indication for valve intervention.

Studied indicate that the autoimmune process involved in RHD begins when the reactive antibodies bind to the valvar endothelium, leading to inflammation and cellular infiltration. Once activated, the valvar endothelium increases the expression of adhesion molecules, which facilitates T-cell binding and infiltration. After the initial valvar insult, the process triggers a cascade leading to the recognition of additional epitopes, leading to progressive valve damage. Evidence that continued presentation of autoantigens at the lesion site contributes to an amplification of the immune response is reinforced by...
the significant reduction in autoantibody levels after surgical removal of the affected leaflets.22

After activation of the valvar endothelium with the adhesion of activated T cells, the scarring, neovascularization and lymphocyte infiltration cycle begins.23 Avascular valvar tissue is normally protected by the endothelium until a triggering factor, which may be antibodies and/or inflammatory cytokines, breaks the endothelial barrier, allowing the cycle of cell infiltration and healing to begin.24 Once initiated, the healing process becomes more intense in the valve interstitium due to the activation and proliferation of myofibroblasts responsible for valve fibrosis.25 It has already been demonstrated that, in view of some pathological conditions such as RHD, interstitial cells can transform into an activated myofibroblast phenotype, expressing inflammatory proteins and cytokines, capable of rapidly remodeling the extracellular environment.26 The significant decrease in plasma levels of biomarkers of collagen metabolism following mitral valve replacement strongly suggests the contribution of the mitral valve apparatus to the perpetuation of the fibrotic process in RHD.19

Figure 2 - Representative histological image of mitral valve from controls and rheumatic heart disease patients stained with hematoxylin-eosin. A) Histological view of a control mitral valve, showing mild fibrosis (arrow). B) Rheumatic mitral valve with severe endocardial (asterisk) and interstitial (arrowhead) fibrosis. Panels C-I show specific aspects of mitral valves from rheumatic heart disease patients. C) Presence of endocardium (arrow) and valvar interstitium (asterisk). In the endocardium, there is mild fibrosis. D) Moderate endocardial fibrosis (arrowhead). Staining: hematoxylin-eosin. E) Neovascularization (arrow) with some inflammatory elements (arrowhead). F) Inflammatory foci (arrow) are detectable within neovascularization foci (asterisk). G) Nodular calcification (asterisk). H) Adipose metaplasia (arrow) with areas of fibrosis (arrowhead).
Calcification was detected in 35% of the rheumatic valves, predominantly in pure mitral stenosis, and correlated with valve area. Calcification was also more frequent in patients with right ventricular dysfunction. The identification of calcification reinforces the chronicity of the process, and its occurrence may be related to the mechanisms underlying the end-stage of rheumatic impairment. 

Rajamannan et al. demonstrated that calcification occurs in areas of neoangiogenesis, stimulated by an active inflammatory process, formed especially by macrophages and myofibroblasts. Banerjee et al. found a greater degree of fibrosis and neovascularization with focal perivascular mild infiltration predominantly of lymphocytes and plasma cells.

**Study limitations**

The small number of patients included in the study is a limitation. However, considering that most rheumatic patients with indication for valve intervention undergo percutaneous valvuloplasty, the number included represents the totality of samples available during the study period.

### Table 2 – Histological data of rheumatic mitral valves and controls

| Variable* | Rheumatic mitral valves (n=40) | Controls (n=20) | p value |
|-----------|--------------------------------|----------------|---------|
| **Endocardium** |                               |                |         |
| Thickness (mm) | 1.3±0.5 | 0.9±0.4 | 0.003 |
| Intensity of inflammation | | | |
| Absent or mild | 9 (22) | 13 (64) | 0.004 |
| Moderate or severe | 31 (78) | 7 (36) |
| Pattern of inflammation | | | |
| Focal | 31 (78) | 7 (36) | 0.004 |
| Intensity of fibrosis | | | |
| Absent or mild | 17 (43) | 19 (35) | 0.001 |
| Moderate or severe | 23 (57) | 1 (5) |
| Pattern of fibrosis | | | < 0.001 |
| Even | 23 (57) | 0 |
| Uneven | 17 (43) | 7 (35) |
| Neoangiogenesis | | | 0.030 |
| | 11 (28) | 0 |
| **Interstitial** | | | |
| Intensity of inflammation | | | 0.321 |
| Absent or mild | 33 (82) | 14 (72) |
| Moderate or severe | 7 (18) | 6 (28) |
| Pattern of inflammation | | | < 0.001 |
| Focal | 37 (92) | 7 (36) |
| Intensity of fibrosis | | | < 0.001 |
| Absent or mild | 0 | 14 (71) |
| Moderate or severe | 40 (100) | 6 (29) |
| Pattern of fibrosis | | | 0.200 |
| Even | 4 (10) | 0 |
| Uneven | 36 (90) | 20 (100) |
| Neoangiogenesis | | | 0.130 |
| | 24 (60) | 7 (35) |
| Calcification | | | 0.010 |
| | 14 (35) | 0 |
| Adipose metaplasia | | | 0.320 |
| | 4 (11) | 4 (21) |

*Data are expressed as means±SD or number (percentage) of patients.

### Table 3 – Histological findings according to the predominant mitral valve lesion

| Variable* | Pure stenosis (n=18) | Regurgitation and combined lesions (n=22) | p value |
|-----------|------------------------|------------------------------------------|---------|
| **Inflammation** | | | 0.900 |
| Absent or mild | 15 (83) | 18 (82) |
| Moderate or severe | 3 (17) | 4 (18) |
| **Neoangiogenesis** | | | 0.897 |
| | 11 (61) | 13 (59) |
| **Calcification** | | | 0.014 |
| | 10 (56) | 4 (18) |
| **Adipose metaplasia** | | | 0.230 |
| | 1 (6) | 4 (18) |

*Data are expressed as number (percentage) of patients.
The high prevalence of atrial fibrillation, previous history of stroke, previous valve intervention, limiting dyspnea (NYHA III and IV) and pulmonary hypertension have been shown to be severe in patients with advanced disease. As we included only patients with indication for valve replacement, our population is, therefore, representative of a spectrum of more severe stages of disease.

Mitral valve replacement is indicated for symptomatic patients with advanced disease and marked valve anatomy deformity, where mitral valve repair is unlikely. Therefore, the sample collected for our study represents the advanced rheumatic process, limiting the evaluation of the process in its initial phase.

The valves from the control group are not healthy, normal valves, since they were collected from patients that had undergone heart transplantation due to severe left ventricular dysfunction of different etiologies. Chagas heart disease, the predominant etiology of valves collected from transplanted hearts, is an inflammatory disease, associated with fibrosis. Although Chagas disease primarily affects the ventricular myocardium, histological valve abnormality may be associated with heart failure. In addition, 35% of patients presented moderate to severe secondary mitral valve regurgitation, which may explain abnormal histological findings. The differences in histological analysis could be even greater if compared to healthy tissue valves.

Clinical implications
The pathological process involved in RHD is complex and still not fully understood. The identification of an active chronic inflammatory process, although of mild intensity, probably responsible for the maintenance of immune response and progression of valve lesion, provides subsidy for additional research, aiming to define strategies that can interrupt the progression of valvular damage and its consequences.

Conclusions
Our findings demonstrate that, despite intense degree of fibrosis, the inflammatory process remains active in the rheumatic mitral valves, even at late disease process with valve...
dysfunction. This inflammation was associated with mitral valve area and left ventricular function. Valvular calcification was more frequent in mitral stenosis and among patients with right ventricular dysfunction, indicating late and severe rheumatic involvement. It is necessary to better understand what maintains the inflammation and how its persistence may predispose to clinical complications as well as the mechanisms that influence RHD mortality.

**Author Contributions**

Conception and design of the research: Gomes NFA, Pascoal-Xavier MA, Passos LSA, Passaglia LG, Dutra WO, Nunes MCP; Acquisition of data and Analysis and interpretation of the data: Gomes NFA, Pascoal-Xavier MA, Passos LSA, Paula TMN, Aguiar JMS, Guarçoni FV, Nassif MCL, Gelape CL, Braulio R, Costa PHN, Martins RB, Dutra WO, Nunes MCP; Statistical analysis: Gomes NFA, Passos LSA, Dutra WO, Nunes MCP; Writing of the manuscript: Gomes NFA, Pascoal-Xavier MA, Passos LSA, Nunes MCP; Critical revision of the manuscript for intellectual content: Gomes NFA, Pascoal-Xavier MA, Passos LSA, Gelape CL, Braulio R, Costa PHN, Passaglia LG, Dutra WO, Nunes MCP.

**Potential Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

**Sources of Funding**

There were no external funding sources for this study.

**Study Association**

This article is part of the thesis of master submitted by Nayana F. A. Gomes, from Universidade Federal de Minas Gerais.

**References**

1. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 2017;377(8):713-22

2. Watkins DA, Beaton AZ, Carapetis JR, Karthikeyan G, Mayosi BM, Wyber R, et al. Rheumatic heart disease worldwide: Jacc scientific expert panel. J Am Coll Cardiol. 2018;72(12):1397-416

3. Leal MT, Passos LS, Guarçoni FV, Aguiar JM, Silva RB, Paula TM, et al. Rheumatic heart disease in the modern era: Recent developments and current challenges. Rev Soc Bras Med Trop. 2019;52

4. Naghavi M, Wang H, Lozano R, Davis A, Liu X, Zou M, et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the global burden of disease study 2013. Lancet. 2015 Jan 7;385(9963):117-27.

5. Zuhlke L, Karthikeyan G, Engel ME, Rangarajan S, Mackie P, Cupido-Katya Mauff B, et al. Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 low- and middle-income countries: Two-year follow-up of the global rheumatic heart disease registry (the remedy study). Circulation. 2016 Nov 8;134(19):1456-66.

6. Zuhlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido-B, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: The global rheumatic heart disease registry (the remedy study). Eur Heart J. 2015 May 7;36(18):1115-22a.

7. Carapetis JR. The stark reality of rheumatic heart disease. Eur Heart J. 2015 May 7;36(18):1070-3.

8. Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet. 2018 Jul 14;392(10142):161-74.

9. Tandon R, Sharma M, Chandrashekhar Y, Kotb M, Yacoub MH, Narula J. Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol. 2013 Mar;10(3):171-7.

10. Mechmeche R, Zaroui A, Aloe S, Boukhris M, Allal-Elasmi M, Katabchi N, et al. Late mitral restenosis after percutaneous commissurotomy: Predictive value of inflammation and extracellular matrix remodeling biomarkers. Heart Lung. 2017;46:258-64

11. Woldu B, Bloomfield GS. Rheumatic heart disease in the twenty-first century. Curr Cardiol Rep. 2016 Oct;18(10):96.

12. Kaplan EL. Pathogenesis of acute rheumatic fever and rheumatic heart disease: Evasive after half a century of clinical, epidemiological, and laboratory investigation. Heart. 2005 Jan;91(1):3-4.

13. Guilherme L, Kohler M, Kalil J. Rheumatic heart disease: Mediation by complex immune events. Adv Clin Chem. 2011;53(2):31-50.

14. Carapetis JR, Beaton A, Cunningham MW, Guilherme L, Karthikeyan G, Mayosi BM, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016;2:15084.

15. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: Cellular mechanisms leading autoimmune reactvity and disease. J Clin Immunol. 2010 Jan;30(1):17-23.

16. Tanasichuk E, Montero MW, Ramous AO, Sampaio RO, Roso VEE, Acconi TA, et al. Atualização das diretrizes brasileiras de valorização: Abordagem das lesões anatomicamente importantes. Arq Bras Cardiol. 2017;109(suppl 2):1-34.

17. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et al. 2014 aha/acc guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 2014 Jun 10;63(22):2438-88.

18. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the american society of echocardiography and the european association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70.

19. Sen U, Banerjee T, Mukherjee S, Ghosh S, Biswas M, Dutta S, et al. Clinical significance of markers of collagen metabolism in rheumatic mitral valve disease. PloS One. 2014 Mar 6;9(3):e90527.

20. Fae KC, Silva DD, Oshiro SE, Tanaka AC, Pomerantzeff PM, Douay C, et al. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol. 2006 May 1;176(9):5662-70.

21. Cunningham MW. Pathogenesis of group A streptococci. J Infect Dis. 2010 Oct 1;202(7):1059-67.

22. Ellis NM, Kutahara DK, Vohra H, Mascaro-Blanco A, Erdem G, Adderson EE, et al. Priming the immune system for heart disease: A perspective on group A streptococci. J Infect Dis. 2010 Oct 1;202(7):1059-67.

23. Roberts S, Kosanke S, Terrence Dunn S, Jankelow D, Duran CM, Cunningham MW. Pathogenic Mechanisms in Rheumatic Carditis: Focus on Valvular Endothelium. J Infect Dis. 2001 Feb 1;183(3):507-11.
24. Martins C, Santos KS, Ferreira FM, Teixeira PC, Pomeranzeff PM, Brandão CM, et al. Distinct mitral valve proteomic profiles in rheumatic heart disease and myxomatous degeneration. Clin Med Insights Cardiol. 2014 Aug 27;8:79-86.

25. Kim I, Kim DK, Yang WI, Shin DH, Jung IM, Park HK, et al. Overexpression of transforming growth factor-β1 in the valvular fibrosis of chronic rheumatic heart disease. J Korean Med Sci. 2008 Feb;23(1):41-8.

26. Levine RA, Hagège AA, Judith DP, Padala M, Dal-Bianco JP, Aikawa E, et al. Mitral valve disease—morphology and mechanisms. Nat Rev Cardiol. 2015 Dec;12(12):689-710.

27. Brasileiro, Filho G: Bogliolo: Patologia. 7 ed. Rio de Janeiro: Guanabara Koogan; 2006. 1472 p.

28. Rajamannan NM. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation. 2005 Jun 21;111(24):3296-301.

29. World Health Organization (WHO). Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation on rheumatic fever and rheumatic heart disease. Geneva; 29 Oct-01- Nov 2001. (WHO Technical Report Series, 923)

30. Andrade JP, Marin-Neto JA, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F, et al. Sociedade Brasileira de Cardiologia. I Diretriz Latino Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica. Arq Bras Cardiol. 2011; 97(2 supl.3): 1-48.